$53 Mln
$-128 Mln
--
As on 29-Sep-2023 16:00 EDT
$0.00
•
-0.60%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Passage Bio (PASG)
| -52.32 | -11.08 | -19.36 | -49.77 | -62.89 | -- | -- |
|
S&P BSE Sensex
| 8.20 | 1.28 | 2.99 | 16.31 | 20.12 | 12.69 | 12.81 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2022
|
2021
|
|
|---|---|---|
|
Passage Bio (PASG)
| -78.27 | -75.17 |
|
S&P BSE Sensex
| 4.44 | 21.99 |
|
S&P BSE Sensex
| 4.44 | 21.99 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Passage Bio Inc. (PASG) stood at $ 230 Mln as on 31-Mar-23
The share price of Passage Bio Inc. (PASG) is $0.658000 (NASDAQ) as of 29-Sep-2023 16:00 EDT. Passage Bio Inc. (PASG) has given a return of -62.89% in the last 3 years.
Passage Bio Inc. (PASG) has a market capitalisation of $ 53 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of Passage Bio Inc. (PASG) is 0.30 times as on 02-Jun-2023, a -0.88% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Passage Bio Inc. (PASG) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Passage Bio Inc. (PASG) and enter the required number of quantities and click on buy to purchase the shares of Passage Bio Inc. (PASG).
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
The CEO & director of Dr. William Chou M.D.. is Passage Bio Inc. (PASG), and CFO & Sr. VP is Dr. James M. Wilson M.D., Ph.D..
The promoters of Passage Bio Inc. (PASG) have pledged 0% of the total equity as on Dec-22.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
498
|
|
|
497
|
|
|
392
|
|
|
383
|
| Passage Bio Inc. (PASG) | Ratios |
|---|---|
|
Return on equity(%)
|
-62.74
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Passage Bio Inc. (PASG) was $-128 Mln.
$52.72 Mln
$0.00 Mln
$-127.65 Mln
$167.77 Mln
$26.95 Mln
High
$0.65 - 1.92
54,632,900
NASDAQ: PASG
Philadelphia, PA
https://www.passagebio.com
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and... gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
